This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
HQP1351
DrugBank Accession Number
DB16185
Background

HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 532.571
Monoisotopic: 532.219844002
Chemical Formula
C29H27F3N6O
Synonyms
  • Hqp-1351 free base
  • Hqp1351 free base
  • Olverembatinib
External IDs
  • D-824
  • GZD-824
  • HQP-1351
  • HQP1351

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
KV1M7Q3CBP
CAS number
1257628-77-5
InChI Key
TZKBVRDEOITLRB-UHFFFAOYSA-N
InChI
InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
IUPAC Name
4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide
SMILES
CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CC5=C(NN=C5)N=C4)=C(C)C=C3)C=C2)C(F)(F)F)CC1

References

General References
Not Available
ChemSpider
29395146
BindingDB
50425780
ChEMBL
CHEMBL2316582
ZINC
ZINC000095594040

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentMyeloid Leukemia, Chronic, Chronic Phase / Olverembatinib / Tyrosine Kinase Inhibitors1
2Active Not RecruitingTreatmentAccelerated phase chronic myologenic leukemia1
2Active Not RecruitingTreatmentMyeloid Leukemia, Chronic, Chronic Phase2
2Not Yet RecruitingTreatmentPhiladelphia-Positive ALL1
2RecruitingTreatmentAccelerated phase chronic myologenic leukemia / Chronic myeloid leukaemia transformation / Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis) / Chronic Myeloid Leukemia in Myeloid Blast Crisis1
2RecruitingTreatmentAcute Leukemia (Category) / Myeloproliferative Neoplasms (MPNs)1
1CompletedTreatmentChronic Myeloid Leukemia (CML)1
1CompletedTreatmentMyeloid Leukemia, Chronic, Chronic Phase1
1Not Yet RecruitingTreatmentLeukemia, Lymphoblastic, Acute, Philadelphia-Positive / Lymphoblastic Leukemia, Acute, Childhood / Refractory Leukemia / Relapsed Leukemia1
1RecruitingTreatmentB Cell Precursor Type Acute Leukemia / Chronic Myeloid Leukemia (CML) / Leukemia, Lymphoblastic, Acute, Philadelphia-Positive / Myeloid Leukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00298 mg/mLALOGPS
logP3.71ALOGPS
logP4.84ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)11.08ChemAxon
pKa (Strongest Basic)7.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area77.15 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity142.85 m3·mol-1ChemAxon
Polarizability55.31 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 15, 2020 18:14 / Updated at December 20, 2020 03:38